Question 1

What are the potential benefits and risks of using QTORIN gel?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations clinical trial (NCT06239480). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations clinical trial (NCT06239480). Contact the study team or your healthcare provider for specific answers.

Question 3

What happens if I experience side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations clinical trial (NCT06239480). Contact the study team or your healthcare provider for specific answers.

Question 4

Can I continue treatment after the 24 weeks if it is effective?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations clinical trial (NCT06239480). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any other treatment options I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations clinical trial (NCT06239480). Contact the study team or your healthcare provider for specific answers.

Question 6

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations clinical trial (NCT06239480). Contact the study team or your healthcare provider for specific answers.

What this study is about